Atsena Therapeutics is a clinical-stage gene therapy company that develops novel treatments for inherited forms of blindness.
Atsena Therapeutics has raised $150.0M in total funding. The most recent round was Series C. The last funding was announced in April 2025.
Atsena Therapeutics's investors include Wellington Management, Lightstone Ventures, OUP (Osage University Partners), Hatteras Venture Partners, Abingworth.
Atsena Therapeutics is headquartered in Durham, United States.
Atsena Therapeutics is a clinical-stage gene therapy company that develops novel treatments for inherited forms of blindness.
Atsena Therapeutics is at the Series C stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Atsena Therapeutics — Funding & Investors." VCBacked, April 2, 2025, https://www.vcbacked.co/company/atsena-therapeutics. Accessed October 29, 2026.
VCBacked. (2025). Atsena Therapeutics — Funding & Investors. Retrieved October 29, 2026, from https://www.vcbacked.co/company/atsena-therapeutics
{{cite web |title=Atsena Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/atsena-therapeutics |website=VCBacked |access-date=October 29, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated